Ksenya V. Shelekhova

Prof. Dr. Ksenya V. Shelekhova

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2006 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
KSKsenya V. Shelekhova
Ksenya V. Shelekhova
DKDmitry V. Kazakov
Dmitry V. Kazakov
Ondrej HesOndrej Hes
Ondrej Hes
VTVladislav Treska
Vladislav Treska
MMMichal Michal
Michal Michal

11 March 2019 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
PDF file
KSKsenya V. Shelekhova
Ksenya V. Shelekhova
KKKirill A. Krykow
Kirill A. Krykow
IMIgor A. Mescherjakov
Igor A. Mescherjakov
NMNikolay P. Mitin
Nikolay P. Mitin
Urothelial cancer is a heterogeneous disease with different molecular pathways that produce distinct molecular subtypes with specific characteristics and patient survival outcomes that require different therapeutic methods. Urothelial tumors in young patients appear to have distinct genetic features compared with their counterparts in older patients. Using a Lund subtype-specific immunohistochemistry panel, we performed molecular subtype profiling of an urothelial carcinoma case series (n = 49) in patients younger than 45 years of age. We demonstrate that the urothelial carcinoma in young patients tends to be of molecular urothelial-like A subtype (80%) and is associated with favorable, recurrent-free survival (P = .022). In the urothelial-like cluster, we identified a portion of patients (10%) with high-grade non–muscle-invasive cancers (so-called urothelial-like D type) that showed significantly higher levels of squamous differentiation and p16, E2F3, and ki67 expression in addition to aberrant expression of Ck20 and a trend toward lower recurrent-free survival (P = .057). Segregation of the cohort according to the decade of occurrence revealed that all tumors (n = 8) of patients younger than 30 years were clearly classified as urothelial-like A subtype. Statistically more aggressive molecular subtypes, such as urothelial-like D and basal/squamous-like (6%) subtypes, were identified in patients older than 30 years of age. Genomically unstable (2%) and mesenchymal-like (2%) subtypes were classified in the 40- to 44-year age group only. These data suggest that more aggressive molecular subtypes of bladder carcinoma appear and become more frequent with age. Further investigations are needed to validate this hypothesis.

28 April 2017 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
KSKsenya V. Shelekhova
Ksenya V. Shelekhova
AZAlexander S. Zhuravlev
Alexander S. Zhuravlev
DKDaria D. Krylova
Daria D. Krylova
AKAlexey S. Konstantinov
Alexey S. Konstantinov
LSLidia V. Shtan
Lidia V. Shtan
VKValeriia A. Kheinshtein
Valeriia A. Kheinshtein
Only 28 cases of pseudomyxoma peritonei (PMP) arising from urachal neoplasms have been reported. We report one example of this extremely rare disease with KRAS mutational status in its spectrum of pathology. A 45-year-old woman presented with urachal frankly invasive mucinous cystadenocarcinoma confined to the dome of the bladder, which clinically manifested as PMP and was not detected at the first surgery. The primary tumour was revealed 6 months later because of its recurrence as PMP. Microscopic investigation revealed tubular adenoma and cystadenocarcinoma communicating with the bladder lumen and transitioning from the urachal urothelium to the mucinous epithelium. A urachal remnant was identified near the neoplasm. On immunohistochemistry, the tumour proved positive for CK7, CK20, CEA, and CDX2. Staining for β-catenin revealed expression in both the cytoplasm and cell membrane. Mismatch repair protein expression was normal. Somatic KRAS-mutation (G12V) was revealed in tubular adenoma, cystadenocarcinoma, and mucinous carcinoma peritonei and may play an oncogenic role in the malignant transformation of urachal mucosa and the development of PMP.

24 December 2018 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
AKAlexey S. Konstantinov
Alexey S. Konstantinov
KSKsenya V. Shelekhova
Ksenya V. Shelekhova
Dedifferentiated liposarcoma shows a wide morphological spectrum. We present a case of dedifferentiated liposarcoma of the spermatic cord in a 66-year-old male that was initially misinterpreted as pseudosarcomatous proliferative funiculitis with mesothelial proliferation.

18 December 2017 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
KSKsenya V. Shelekhova
Ksenya V. Shelekhova
VEVitaly V. Egorenkov
Vitaly V. Egorenkov
VKValery A. Kheinstein
Valery A. Kheinstein
AKAnastasia M. Konstantinova
Anastasia M. Konstantinova
AIAglaya Iyevleva
Aglaya Iyevleva
DMDmitry E. Matsko
Dmitry E. Matsko
Primary extraspinal myxopapillary ependymoma (MPE) is an exceptionally rare lesion that is mainly located in the subcutaneous sacrococcygeal region. We describe the first case of MPE that presented as an intramuscular tumor mass located in the lumbar area. Absence of the visible connection with the spinal cord and lack of any other tumors in the reported case argue for the primary ectopic origin of the MPE. The differential diagnosis of MPE is discussed. Additionally, we evaluated the expression level of molecular biomarkers that have a prognostic value in central nervous system tumors.

Verified
Journal Article
Open access
PDF file
ASAnna Sokolenko
Anna Sokolenko
FMFedor Moiseenko
Fedor Moiseenko
AIAglaya G. Iyevleva
Aglaya G. Iyevleva
AIAlexandr O. Ivantsov
Alexandr O. Ivantsov
GDGeorgiy D. Dolmatov
Georgiy D. Dolmatov
EIEvgeny N. Imyanitov
Evgeny N. Imyanitov
Neoadjuvant chemotherapy (NACT) for breast cancer (BC) often results in pathologic complete response (pCR), i.e., the complete elimination of visible cancer cells. It is unclear whether the use of ultrasensitive genetic methods may still detect residual BC cells in complete responders. Breast carcinomas arising in BRCA1 mutation carriers almost always carry alterations of the TP53 gene thus providing an opportunity to address this question. The analysis of consecutive BC patients treated by NACT revealed a higher pCR rate in BRCA1-driven vs. BRCA1-wildtype BCs (13/24 (54%) vs. 29/192 (15%), p < 0.0001). Twelve pre-/post-NACT tissue pairs obtained from BRCA1 mutation carriers were available for the study. While TP53 mutation was identified in all chemonaive tumors, droplet digital PCR (ddPCR) analysis of the post-NACT tumor bed revealed the persistence of this alteration in all seven pCR-non-responders but in none of five pCR responders. Eleven patients provided to the study post-NACT tissue samples only; next-generation sequencing (NGS) analysis revealed mutated TP53 copies in all six cases without pCR but in none of five instances of pCR. In total, TP53 mutation was present in post-NACT tissues in all 13 cases without pCR, but in none of 10 patients with pCR (p < 0.000001). Therefore, the lack of visible tumor cells in the post-NACT tumor bed is indeed a reliable indicator of the complete elimination of transformed clones. Failure of ultrasensitive methods to identify patients with minimal residual disease among pCR responders suggests that the result of NACT is a categorical rather than continuous variable, where some patients are destined to be cured while others ultimately fail to experience tumor eradication.